drugset / Trial / NCT02864628
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
RandomizedParallel-groupSingle-blindPrevention
Summary
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-10-27
- Completion
- 2017-10-27
Outcome
Outcome not reported
Stopped: “Protocol was withdrawn from IND”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVA-BN-RSV | Vaccine | 5e+07 unknown | Intranasal |
| Subject | MVA-BN-RSV | Vaccine | 1e+08 unknown | Intranasal |
| Subject | MVA-BN-RSV | Vaccine | 5e+08 unknown | Intranasal |